Comparison of the CHADS2, CHA2DS2 -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial

Stavros Apostolakis; Deirdre A. Lane; Harry Buller; Gregory Y. H. Lip

doi:10.1160/TH13-07-0552

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2013; 110(05): 1074-1079
DOI: 10.1160/TH13-07-0552

New Technologies, Diagnostic Tools and Drugs

Schattauer GmbH

Comparison of the CHADS₂, CHA₂DS₂ -VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial

Stavros Apostolakis

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

,

Deirdre A. Lane

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

,

Harry Buller

²Department of Vascular Medicine, Academic Medical Centre, Amsterdam, Netherlands

,

Gregory Y. H. Lip

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK

› Institutsangaben

Abstract

Summary

Many of the risk factors for stroke in atrial fibrillation (AF) are also important risk factors for bleeding. We tested the hypothesis that the CHADS₂ and CHA₂DS₂-VASc scores (used for stroke risk assessment) could be used to predict serious bleeding, and that these scores would compare well against the HAS-BLED score, which is a specific risk score designed for bleeding risk assessment. From the AMADEUS trial, we focused on the trial’s primary safety outcome for serious bleeding, which was “any clinically relevant bleeding”. The predictive value of HAS-BLED/CHADS₂/CHA₂DS₂-VASc were compared by area under the curve (AUC, a measure of the c-index) and the Net Reclassification Improvement (NRI). Of 2,293 patients on VKA, 251 (11%) experienced at least one episode of “any clinically relevant bleeding” during an average 429 days follow up period. Incidence of “any clinically relevant bleeding” rose with increasing HAS-BLED/CHADS₂/CHA₂DS₂-VASc scores, but was statistically significant only for HAS-BLED (p<0.0001). Only HAS-BLED demonstrated significant discriminatory performance for “any clinically relevant bleeding” (AUC 0.60, p<0.0001). There were significant AUC-differences between HAS-BLED (which had the highest AUC) and both CHADS₂ (p<0.001) and CHA₂DS₂VASc (p=0.001). The HAS-BLED score also demonstrated significant NRI for the outcome of “any clinically relevant bleeding” when compared with CHADS₂ (p=0.001) and CHA₂DS₂-VASc (p=0.04). In conclusion, the HAS-BLED score demonstrated significant discriminatory performance for “any clinically relevant bleeding” in anticoagulated patients with AF, whilst the CHADS₂ and CHA₂DS₂-VASc scores did not. Bleeding risk assessment should be made using a specific bleeding risk score such as HAS-BLED, and the stroke risk scores such as CHADS₂ or CHA₂DS₂-VASc scores should not be used.

Keywords

Atrial fibrillation - bleeding risk - oral anticoagulation - HAS-BLED - CHADS₂ - CHA₂DS₂-VASc

Volltext

Referenzen

References
1 Apostolakis S, Lane DA, Guo Y. et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J Am Coll Cardiol 2012; 60: 861-867.
2 Lip GY, Banerjee A, Lagrenade I. et al. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol 2012; 5: 941-948.
3 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
4 Omran H, Bauersachs R, Rübenacker S. et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012; 108: 65-73.
5 Lip GY, Andreotti F, Fauchier L. et al. European Heart Rhythm Association. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association. [EHRA] endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
6 Poli D, Antonucci E, Marcucci R. et al. Risk of bleeding in very old atrial fibrillation patients on warfarin: relationship with ageing and CHADS2 score. Thromb Res 2007; 121: 347-352.
7 Hylek EM, Evans-Molina C, Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
8 Wilke T, Groth A, Mueller S. et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
9 Holt TA, Hunter TD, Gunnarsson C. et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract 2012; 62: e710-717.
10 Olesen JB, Lip GY, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
11 Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298-2307.
12 Pradaxa Prescribing Information, Taiwan Food and Drug Administration. Available at: http://www.fda.gov.tw/MLMS/(S(nmvmo245foj0qw55kb0ae4bi))/ShowFile.aspx?LicId=02025458&Seq=002&Type=9 Accessed June 12 2013
13 AMADEUS Investigators Bousser MG, Bouthier J, Büller HR. et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371: 315-321.
14 DeLong ER, De Long DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
15 Pencina MJ, D' Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010; 48: 1703-1711.
16 Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26: 565-574.
17 Oldgren J, Alings M, Darius H. et al. RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011; 155: 660-667.
18 Gallego P, Roldán V, Torregrosa JM. et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 5: 312-318.
19 Roldán V, Marín F, Fernández H. et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143: 179-184.
20 Lip GY, Lin HJ, Hsu HC. et al. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: The Chin-Shan Community Cohort Study. Int J Cardiol. 2013 Epub ahead of print
21 Smith JG, Wieloch M, Koul S. et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention 2012; 8: 672-678.
22 Olesen JB, Pisters R, Roldans V. et al. The ATRIA risk scheme to predict warfarin-associated hemorrhage not ready for clinical use. J Am Coll Cardiol 2012; 59: 194-195.
23 Patel MR, Mahaffey KW, Garg J. et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.